Streetbeat News

Products Services

ANAB

GILD

LLY

HC Wainwright initiated coverage on AnaptysBio Inc (NASDAQ:ANAB) with a Buy rating and a price target of $55, citing potential superior efficacy of its investigational arthritis drug rosnilimab compared to Eli Lilly's (NYSE:LLY) peresolimab. Gilead Sciences Inc (NASDAQ:GILD) also mentioned for its BTLA agonist study expansion.

Portfolio Pulse from Vandana Singh

July 22, 2024 | 6:53 pm

DAL

Delta Air Lines expects more flight cancellations this week, potentially impacting its operations and customer satisfaction.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 6:52 pm

MSTR

TSLA

Elon Musk's change of his social media profile picture to a 'Dark MAGA' meme featuring Donald Trump with laser eyes caused the Dark Maga (DMAGA) meme coin to surge 4,300% in 24 hours. This led to significant gains for some traders. Michael Saylor also commented on the trend, linking it to Bitcoin.

Portfolio Pulse from Khyathi Dalal

July 22, 2024 | 6:52 pm

IONS

Ionis Pharmaceuticals shares are trading higher after the company announced positive results from its phase 1/2 open-label study of Angelman Syndrome, showing 97% of patients in the medium and high dose groups saw improvement in symptoms.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 6:47 pm

AMR

BTU

HCC

ITOCY

NGLOY

PKX

WHITF

Coal prices are expected to rise in late summer and fall due to supply outages in Australia and the US. Key incidents include mine fires in Australia and West Virginia, and a lock and dam closure in Alabama. These disruptions will tighten supply, potentially benefiting coal producers like Anglo American, Peabody Energy, Warrior Met Coal, Alpha Metallurgical Resources, and Whitehaven Coal.

Portfolio Pulse from Matt Whittaker

July 22, 2024 | 6:31 pm

AAL

CRWD

DAL

LUV

MSFT

UAL

Southwest Airlines (NYSE:LUV) avoided the recent Microsoft (NASDAQ:MSFT) and CrowdStrike (NASDAQ:CRWD) outages that grounded competitors like Delta (NYSE:DAL), United (NASDAQ:UAL), and American Airlines (NASDAQ:AAL) due to its outdated software systems. This resilience could positively impact Southwest's upcoming earnings report.

Portfolio Pulse from Chris Katje

July 22, 2024 | 6:08 pm

BTCUSD

10x Research advises against shorting Bitcoin ahead of former President Donald Trump's speech at the Bitcoin 2024 conference, suggesting it could trigger a parabolic move if Bitcoin trades above its previous all-time high. Rumors of Trump announcing Bitcoin as a strategic reserve asset and the potential for a pro-crypto administration could significantly impact the market.

Portfolio Pulse from Murtuza Merchant

July 22, 2024 | 6:05 pm

SAVA

Cassava Sciences Inc (NASDAQ:SAVA) is advancing its Alzheimer's drug, simufilam, through Phase 3 trials. The trials are crucial for determining the drug's efficacy and safety, with results expected by December 2024 and June 2025. The company faces ongoing investigations by the DOJ and SEC, and the credibility of its clinical trial results has been questioned by the FDA.

Portfolio Pulse from Vandana Singh

July 22, 2024 | 6:03 pm

CSB

POR

SCAP

KeyBanc Capital Markets upgraded Portland General Electric Company (NYSE:POR) to Overweight with a $52 price target due to strong power demand growth from high-tech and semiconductor industries, and improved earnings from updates to the power cost recovery mechanism. The company is also managing a larger RFP for capacity, which could boost growth. Investors can gain exposure via Series Portfolios Trust InfraCap Small Cap Income ETF (NYSE:SCAP) and VictoryShares US Small Cap High Div Volatility Wtd ETF (NASDAQ:CSB).

Portfolio Pulse from Lekha Gupta

July 22, 2024 | 5:49 pm

LLY

NVO

PFE

RHHBY

The development of oral weight loss medications is gaining momentum with companies like Eli Lilly, Novo Nordisk, Pfizer, and Roche leading the charge. While oral drugs offer advantages over injectables, such as reduced costs and no need for refrigeration, they face challenges like production issues and potential side effects. Novo Nordisk's Rybelsus is currently the only authorized oral GLP-1 drug, but other companies are making significant progress in clinical trials.

Portfolio Pulse from Vandana Singh

July 22, 2024 | 5:42 pm